<p>週四，uniQure 的股票在 FDA 表示缺乏足夠證據批准其亨廷頓基因療法的消息後，經歷了顯著下跌。FDA 的拒絕導致 uniQure 的股票再次下跌，表明公司面臨嚴峻的挑戰。這一消息突顯了 uniQure 亨廷頓病治療前景的不確定性。</p>

QURE

<p>在週四，UniQure 的股票在 FDA 表示缺乏足夠證據以批准其亨廷頓基因療法的消息後，經歷了顯著下跌。FDA 的拒絕導致 UniQure 的股票再次下跌，表明該公司面臨着嚴峻的局面。這一消息突顯了圍繞 UniQure 亨廷頓病治療前景的不確定性</p>

<p>On Thursday, UniQure stock experienced a significant decrease following news that the FDA has stated insufficient evidence for the approval of their Huntington's gene therapy. The rejection from the FDA has caused another drop in UniQure's stock, indicating a challenging situation for the company. This news emphasizes the uncertainty surrounding the fate of UniQure's treatment for Huntington's disease.</p>
<div class="lb-trans"><p>週四，uniQure 的股票在 FDA 表示缺乏足夠證據批准其亨廷頓基因療法的消息後，經歷了顯著下跌。FDA 的拒絕導致 uniQure 的股票再次下跌，表明公司面臨嚴峻的挑戰。這一消息突顯了 uniQure 亨廷頓病治療前景的不確定性。</p>
</div>

由於 FDA 表示證據不足以批准亨廷頓病的治療，UniQure 的股票大幅下跌